Danazol in treatment of angio-immunoblastic lymphadenopathy

S D Banavali; Shripad Banavali; Purvish M. Parikh; P M Parikh; Prashant M. Parikh; B S Charak; Bishan S. Charak; Alok Modi; A Modi; R Iyer; Rajaraman Iyer; Kanchan S. Nadkarni; K S Nadkarni; T Saikia; Tapan Saikia; R. Gopal; Chitralekna S. Soman; C S Soman; S H Advani; Suresh H. Advani

doi:10.1002/1097-0142(19890801)64:3<613::aid-cncr2820640308>3.0.co;2-k

Danazol in treatment of angio-immunoblastic lymphadenopathy

S D Banavali, Shripad Banavali, Purvish M. Parikh, P M Parikh, Prashant M. Parikh, B S Charak, Bishan S. Charak, Alok Modi, A Modi, R Iyer, Rajaraman Iyer, Kanchan S. Nadkarni, K S Nadkarni, T Saikia, Tapan Saikia, R. Gopal, Chitralekna S. Soman, C S Soman, S H Advani, Suresh H. Advani

Cancer · 1989 · vol. 64(3) , pp. 613–615 · doi:10.1002/1097-0142(19890801)64:3<613::aid-cncr2820640308>3.0.co;2-k · PMID:2743256 · W2092120314

Case report OA: closed CC0

View on OpenAlex View on PubMed View at publisher

⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

This paper describes a patient with angio-immunoblastic lymphadenopathy who achieved complete remission using a danazol-based regimen, suggesting a potential non-cytotoxic treatment option.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The clinical manifestations of angio-immunoblastic lymphadenopathy (AILD) suggest that there is an abnormality in the immune system. Most patients with AILD die from opportunistic infections associated with lymphocyte depletion. As chemotherapy further increases the already high susceptibility of infections, the therapeutic management of AILD is difficult. The achievement of complete remission (CR) by the patient described here using a danazol-based regimen raises the hope that treatment of this disease with a noncytotoxic drug may be possible. The rationale behind and advantages of using danazol are discussed.

My notes (saved in your browser only)

Condition tags

die_deep_infiltrating

MeSH descriptors

Danazol Immunoblastic Lymphadenopathy Pregnadienes Danazol Female Humans Immunoblastic Lymphadenopathy Middle Aged Pregnadienes Remission Induction

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

References (23)

Danazol therapy for autoimmune hemolytic anemia via openalex
Efficacy of danazol in pure red cell aplasia via openalex
doi:10.1016/0002-9343(79)90788-5 via openalex
doi:10.1016/0002-9343(75)90466-0 via openalex
W30538064 via openalex
W244945877 via openalex
W2346641483 via openalex
W3144824096 via openalex
doi:10.1002/1097-0142(197802)41:2<578::aid-cncr2820410226>3.0.co;2-8 via openalex
doi:10.1159/000206176 via openalex
doi:10.1002/1097-0142(19800601)45:11<2843::aid-cncr2820451121>3.0.co;2-c via openalex
doi:10.7326/0003-4819-93-6-809 via openalex
doi:10.1016/0090-1229(87)90016-x via openalex
doi:10.1056/nejm198306093082306 via openalex
doi:10.1016/s0140-6736(74)90553-4 via openalex
doi:10.1002/1097-0142(197802)41:2<507::aid-cncr2820410218>3.0.co;2-d via openalex
doi:10.1056/nejm197501022920101 via openalex
doi:10.1002/1097-0142(19871115)60:10<2412::aid-cncr2820601010>3.0.co;2-f via openalex
doi:10.1016/s0140-6736(83)92129-3 via openalex
doi:10.1002/1097-0142(19830715)52:2<318::aid-cncr2820520221>3.0.co;2-g via openalex
doi:10.1093/oxfordjournals.qjmed.a067563 via openalex
doi:10.1073/pnas.81.2.593 via openalex
doi:10.1136/jcp.39.11.1229 via openalex

Source provenance

openalex: last seen: 2026-05-14T06:02:11.780192+00:00
pubmed: last seen: 2026-10-08T21:18:11.460223+00:00
unpaywall: last seen: 2026-10-19T06:34:38.229974+00:00

License: CC0 · commercial use OK

[1] Danazol therapy for autoimmune hemolytic anemia 1985

[2] Efficacy of danazol in pure red cell aplasia 1986